Updated: Moderna rounds out 2022 with $18.4B in vaccine sales, boosts R&D budget for 2023
Moderna CEO Stéphane Bancel is revving the engines going into 2023, with a whopping $4.5 billion R&D budget and a new priority review voucher.
The company’s full-year sales totaled $18.4 billion, it announced on Monday, falling shy of the chief executive’s previous $21 billion projections. Bancel cited delivery delays, short-term supply shortages and a “very complex third quarter from a manufacturing standpoint” upon lowering the guidance last quarter, while promising that the company is “in a much better place” for 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.